BIOR

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics (BIOR - Research Report), with a price target of $6.00. The company's shares closed yesterday at $0.28.Pantginis covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Actinium Pharmaceuticals, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of -16.9% and a 30.95% success rate on recommended stocks. Currently, the analyst consensus on Biora Therapeutics is a Moderate Buy with an average price target of $6.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $6.20 and a one-year low of $0.24.
https://www.tipranks.com/news/blurbs/biora-therapeutics-bior-gets-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral